Calithera Biosciences to Participate in the JMP Securities 2017 Life Sciences Conference
June 14 2017 - 7:00AM
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage
pharmaceutical company focused on discovering and developing novel
small molecule drugs directed against tumor metabolism and tumor
immunology targets for the treatment of cancer, today announced
that Susan Molineaux, Ph.D., President and Chief Executive Officer
of Calithera, will participate in the upcoming JMP Securities 2017
Life Sciences Conference.
Dr. Molineaux will participate in a panel
discussion entitled, “Immuno-Oncology Combination Strategies,” on
Wednesday, June 21, 2017 at 10:00 a.m. EDT. The conference
will be held in New York, NY.
About Calithera Calithera
Biosciences, Inc. is a clinical-stage pharmaceutical company
focused on discovering and developing novel small molecule drugs
directed against tumor metabolism and tumor immunology targets for
the treatment of cancer. Calithera’s lead product candidate,
CB-839, is an inhibitor of glutaminase. CB-839 takes advantage of
the pronounced dependency many cancers have on the nutrient
glutamine for growth and survival. It is currently being evaluated
in Phase 1/2 clinical trials in combination with standard of care
agents. CB-1158 is an investigational immuno-oncology metabolic
checkpoint inhibitor designed to target arginase, a critical
immunosuppressive enzyme responsible for T-cell suppression by
myeloid-derived suppressor cells (MDSCs). Arginase depletes
arginine, a nutrient that is critical for the activation, growth
and survival of the body’s cancer-fighting immune cells, known as
cytotoxic T-cells. CB-1158 is being developed in collaboration with
Incyte Corporation and is currently in a Phase I clinical trial.
Calithera is headquartered in South San Francisco, California. For
more information about Calithera, please visit
http://www.calithera.com/.
Forward Looking
StatementsStatements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as "may,"
"will," "expect," "anticipate," "estimate," "intend," "poised" and
similar expressions (as well as other words or expressions
referencing future events, conditions, or circumstances) are
intended to identify forward-looking statements. These
statements include those related to the Company’s clinical pipeline
of novel cancer therapies. Because such statements are
subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. The potential product candidates that Calithera
develops may not progress through clinical development or receive
required regulatory approvals within expected timelines or at all.
In addition, clinical trials may not confirm any safety, potency or
other product characteristics described or assumed in this press
release. Such product candidates may not be beneficial to
patients or successfully commercialized. The failure to meet
expectations with respect to any of the foregoing matters may have
a negative effect on Calithera's stock price. Additional
information concerning these and other risk factors affecting
Calithera's business can be found in Calithera's most recent
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission, and other periodic filings with the Securities
and Exchange Commission at www.sec.gov. These forward-looking
statements are not guarantees of future performance and speak only
as of the date hereof, and, except as required by law, Calithera
disclaims any obligation to update these forward-looking statements
to reflect future events or circumstances.
Contact:
Jennifer McNealey
ir@Calithera.com
650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2023 to Apr 2024